US/UK/Canada

Share

Contacts

  • Mark Waugh

    CEO


    +1 (260) 804-1342

    • Links

    Pick a time period -
    Tags ( Active)

    OssDsign AB (publ) publishes year-end report 2025

    Strong growth and real-world data set the stage for U.S. market expansionOssDsign AB (publ) announces that the year-end report for 2025 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release.  The year-end 2025 results will also be presented at an investor webcast today February 3rd at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q4-2025/ 

    Performance of OssDsign Catalyst® in a patient with post-traumatic ankle arthritis showcased in medical journal

    Uppsala, Sweden, September 2, 2025. OssDsign AB (publ.) today announces that a case study of OssDsign Catalyst® as a bone void filler to augment total ankle arthroplasty in a patient with post-traumatic ankle arthritis has been published in the Biomedical Journal of Scientific & Technical Research.The rationale for the use of Catalyst Bone Graft for this patient, in addition to its ease of handling for the surgeon, was related to its mechanism of action, which includes both endochondral and intram­embranous ossification. The authors conclude that at three months follow up, CT scans show

    Exercise period starts in OssDsign’s long-term incentive warrant program 2022/2025, boosting the company’s cash position by up to SEK 10 million

    Uppsala, July 1, 2025. OssDsign AB (publ.) announces that the exercise period for the long-term incentive warrant program 2022/2025 starts today on July 1.Approximately 1.5 million warrants have been issued to board members, executives and employees as part of the long-term incentive program adopted at OssDsign’s Annual General Meeting in 2022. According to the program, warrants can be exercised to buy shares (1 share per warrant) between July and December 2025. If all warrants are converted to shares, the company will receive approximately SEK 10 million.   In conjunction with the

    Revised proposal for election of the board of directors in OssDsign

    Uppsala, June 9, 2025. OssDsign AB (publ.) today announces, through the nomination committee, a revised proposal for election of the board of directors at the annual general meeting on June 11, 2025.In the notice convening the annual general meeting in OssDsign AB (publ) (the “Company”), to be held on 11 June 2025, the nomination committee proposed re-election of Simon Cartmell (also proposed to be re-elected as chairman), Christer Fåhraeus, Jill Schiaparelli and Newton Aguiar, and new-election of David Jern, as ordinary members of the board of directors.   The nomination committee

    OssDsign has carried out a directed share issue of approximately SEK 158 million

    June 3, 2025, 23:04 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) has completed a directed share issue of 11,500,000 shares at a subscription price of SEK 13.75 per share (the “Directed Issue”), through which the Company receives approximately SEK 158 million before deduction of transaction costs. The subscription price was determined based on an accelerated book-building procedure lead by DNB Carnegie Investment Bank AB (“DNB Carnegie”).NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG,

    OssDsign explores the conditions for increasing the scope of the directed share issue to approximately 11.5 million shares

    June 3, 2025, 19:35 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) earlier today informed that the Company has mandated DNB Carnegie Investment Bank AB (“DNB Carnegie”) to evaluate the conditions for carrying out a new share issue of approximately 9 million shares directed towards Swedish and international institutional investors (the “Directed Share Issue”). The interest in participating in the Directed Share Issue has been strong and OssDsign has therefore decided to investigate the conditions for increasing the scope to approximately 11.5 million shares.NOT FOR RELEASE,

    OssDsign included in MSCI index

    Uppsala, May 14, 2025. Today, OssDsign AB (publ.) today announces that the company’s share will be included in the MSCI Global Micro Cap Index, implemented as of the close of May 30, 2025.MSCI provides decision support and services to the global investment community and conducts quarterly updates of its equity indexes. In the latest revision, OssDsign has been included in the MSCI Global Micro Cap Index, implemented as of the close of May 30. Based on MSCI’s expertise in research, data and technology, equity indexes of global shares are revised continuously to support clients’ investment

    10,000 patients treated with OssDsign Catalyst® in the U.S.

    Uppsala, May 12, 2025. Today, OssDsign AB (publ.) announces that it has reached its milestone of 10,000 patients treated with the innovative nanosynthetic bone graft, OssDsign Catalyst, confirming its continued success in the U.S. orthobiologics market.The continuous and rapid increase in treated patients is a strong testament to how well OssDsign Catalyst has been received in the U.S. market since its launch in August 2021. ” With 10,000 patients treated, the adoption of OssDsign Catalyst is clearly accelerating. This is a substantial increase from the 5,000 patients reported in May

    Groundbreaking Study Highlights Enhanced Bone Formation with Novel Silicate-Containing Synthetic Bone Grafts

    Uppsala, April 11, 2025. OssDsign® AB (publ.) today announces that a new preclinical study comparing the bone-forming potential of different silicate-containing calcium phosphate synthetic bone grafts has been published in the peer-reviewed scientific journal Journal of Orthopaedic Surgery and Research. The study demonstrates that OssDsign Catalyst® is the first clinically available synthetic bone graft to successfully generate robust, functional bone in challenging avascular environments at early time points.A research team led by Professor Iain R. Gibson from the University of Aberdeen

    24-month follow up data from the clinical study of OssDsign Catalyst® show 100% spinal fusion

    Uppsala, April 9, 2025. OssDsign AB (publ.) today announces that the 24-month follow up results from the clinical study TOP FUSION will be published in the peer-reviewed journal, Biomedical Journal of Scientific & Technical Research. The results demonstrate a 100% spinal fusion rate and improved quality of life and pain after surgery with the innovative nanosynthetic bone graft OssDsign Catalyst.The data, soon to be published in the peer-reviewed journal, Biomedical Journal of Scientific & Technical Research, demonstrates that using OssDsign Catalyst leads to consistent and rapid bone

    OssDsign reaches its target of 300 patients enrolled in the prospective spinal fusion registry PROPEL

    Uppsala, February 25, 2025. OssDsign AB (publ.) today announced that the company has reached its target of 300 enrolled patients in the multi-center, prospective spinal fusion registry PROPEL. This registry, initiated in March 2022, collects real-world data from patients treated with OssDsign Catalyst."When we initiated the PROPEL registry, we communicated a target of 300 patients. Reaching this milestone already confirms our capability to gather clinically relevant data and the successful enrollment is a direct result of surgeons' high interest in collaborating with OssDsign to evaluate

    OssDsign AB (publ) publishes Q3 2024 Interim Report and raises guidance on gross margin

    OssDsign AB (publ) announces that the interim report for Q3 2024 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release.The Q3 2024 results will also be presented at an investor webcast today November 12th at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q3-2024-2/or via the OssDsign website.     The third quarter in figures   · Net sales amounted to TSEK 35,728 (31,697). As all sales now derive from orthobiologics, which in the corresponding

    OssDsign AB (publ) publishes Q2 2024 Interim Report

    Reaching milestone in orthobiologics salesOssDsign AB (publ) announces that the interim report for Q2 2024 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release.The Q2 2024 results will also be presented at an investor webcast today August 20th at 11:00 CET. The webcast can be accessed via the following link: www.finwire.tv/webcast/ossdsign/q2-2024/ or via the OssDsign website.    The second quarter in figures   · Net sales amounted to TSEK 29,737 (23,997), corresponding to a growth of 143%, or 139%

    Withdrawal of proposed incentive programs and revised proposal on board composition and fees ahead of AGM in OssDsign

    The board of directors of OssDsign AB, following discussions with a larger group of major shareholders, announces the withdrawal of the proposed incentive programs and the nomination committee’s revised proposal as regards election of and fees payable to board members ahead of the annual general meeting.PRESS RELEASEOssDsign ABUppsala, 24 June, 2024  On 24 May 2024, the notice to OssDsign’s annual general meeting, to be held on 25 June 2024 in Stockholm, was published. In the notice, two (2) different share related incentive programs were proposed for employees and contractors and

    5,000 patients treated with OssDsign Catalyst® in the U.S.

    Uppsala, May 30, 2024. Today, OssDsign AB (publ.) announces that the company continues its successful penetration of the U.S. orthobiologics market. To date, 5,000 patients have been treated with the innovative nanosynthetic bone graft OssDsign Catalyst.The continuous and rapid increase in treated patients is a strong testament to how well OssDsign Catalyst has been received in the U.S. market since its launch in August 2021.   “With 5,000 patients treated, the use of OssDsign Catalyst is not just growing, it's accelerating. This is a significant leap from the earlier announcements of

    OssDsign Catalyst becomes universally available to all Military Treatment Facilities in the U.S. via ECAT

    OssDsign AB (publ.) today announces that the company’s nanosynthetic bone graft, OssDsign Catalyst has been included in the Department of Defense’s Military Health System’s electronic catalogue (ECAT), which means that the product is now universally available and can be ordered directly from any of the more than 50 Military Treatment Facilities in the U.S.The uptake of OssDsign Catalyst in ECAT has been mediated through the previously communicated collaboration with Red One Medical, a private-sector scout of medical innovation for the Department of Veterans Affairs (VA) and the Department

    OssDsign has carried out a directed share issue of approximately SEK 150 million

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. 26 SEPTEMBER 2023, 22:30 CEST OssDsign AB (publ) (”OssDsign” or the ”Company”) has completed a directed share issue of 26,315,790 shares at a subscription price of SEK 5.7 per share (the “Directed Issue”

    OssDsign explores the conditions to carry out a directed share issue

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. 26 SEPTEMBER 2023, 17:32 CEST OssDsign AB (publ) (”OssDsign” or the ”Company”) intends to explore the conditions to carry out a directed share issue corresponding to approximately SEK 150 million

    OssDsign announces strategic shift to become a pure play orthobiologics company

    Uppsala, September 26, 2023, 17:31 CEST. OssDsign AB (publ) today announced a strategic shift to focus its operations on the orthobiologics business in the U.S, in order to increase shareholder value. The new strategy means that OssDsign will become a pure play orthobiologics company focusing on the nanosynthetic bone graft OssDsign Catalyst, an off-the-shelf product characterized by high scalability and high gross margins at 90 percent or above. All activities pertaining to the company’s patient-specific cranial implant business will be discontinued in a responsible manner by the end of

    OssDsign® Catalyst receives clearance from FDA for major new indication for use in interbody cages

    Uppsala, Sweden, September 18, 2023. OssDsign AB (publ.) today announces that the company’s innovative nanosynthetic bone graft OssDsign Catalyst has received clearance for use in interbody cages in spinal surgery from the U.S. Food and Drug Administration (FDA), allowing surgeons to use OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone.“This decision by the FDA represents one of the most important events in the history of

    2,000 patients treated with OssDsign® Catalyst in the U.S.

    Uppsala, September 13, 2023. OssDsign AB (publ.) today announces that the company’s orthobiologic business continues to accelerate its successful commercialization in the U.S. To this day, 2,000  patients have been treated with the innovative nanosynthetic bone graft OssDsign Catalyst, up from 1,000 patients treated in May.With 2,000 patients treated, OssDsign Catalyst continues to show exponential growth from earlier records of 1,000 treated patients in May and 500 patients treated in January.   “It is great to see how our orthobiologics business continues its successful

    OssDsign surpasses 200 patients in its prospective spinal fusion registry PROPEL

    Uppsala, August 16, 2023. OssDsign AB (publ.) today announces that the company has enrolled 200 patients in the multi-center, prospective spinal fusion registry, PROPEL. The registry was initiated in March 2022, to gather real-world data from patients who have been treated with OssDsign Catalyst."This important milestone reflects our ability to collect clinically relevant data and is a direct result of the high level of interest from surgeons to continue using OssDsign Catalyst, resulting in a growing number of patients being included in PROPEL. The collection of robust clinical evidence is

    1,000 patients treated with OssDsign® Catalyst in the U.S.

    Uppsala, May 9, 2023. OssDsign AB (publ.) today announces that 1,000 patients have been treated in the U.S. with the innovative nanosynthetic bone graft OssDsign Catalyst. Product awareness is increasing considerably, which is reflected in the rapidly growing number of patients treated.OssDsign Catalyst has been very well received in the U.S. market since its launch in August 2021. In January OssDsign reported that 500 patients had been treated since launch, and at the beginning of May the number increased to 1,000 patients.  “OssDsign Catalyst is growing exponentially driven by a

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media